Goldman Sachs Group Inc. Has $159,000 Stake in Zura Bio Limited $ZURA

Goldman Sachs Group Inc. decreased its holdings in Zura Bio Limited (NASDAQ:ZURA) by 14.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 122,976 shares of the company’s stock after selling 21,107 shares during the quarter. Goldman Sachs Group Inc. owned 0.18% of Zura Bio worth $159,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Millennium Management LLC raised its stake in Zura Bio by 1,499.0% in the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock worth $1,753,000 after purchasing an additional 657,420 shares in the last quarter. Allostery Investments LP increased its holdings in Zura Bio by 44.2% in the 1st quarter. Allostery Investments LP now owns 2,329,384 shares of the company’s stock valued at $3,005,000 after buying an additional 714,258 shares during the period. ProShare Advisors LLC bought a new position in Zura Bio in the 4th quarter valued at about $35,000. Two Sigma Advisers LP bought a new position in Zura Bio in the 4th quarter valued at about $32,000. Finally, ADAR1 Capital Management LLC increased its holdings in Zura Bio by 34.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company’s stock valued at $3,614,000 after buying an additional 723,933 shares during the period. Institutional investors and hedge funds own 61.14% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ZURA. Oppenheimer decreased their target price on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, August 15th. Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a report on Friday, August 15th. Finally, HC Wainwright decreased their target price on shares of Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.60.

Zura Bio Price Performance

ZURA opened at $2.99 on Tuesday. Zura Bio Limited has a fifty-two week low of $0.97 and a fifty-two week high of $5.07. The firm has a market capitalization of $194.41 million, a price-to-earnings ratio of -4.27 and a beta of -0.02. The company’s 50 day moving average price is $1.87 and its two-hundred day moving average price is $1.46.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. As a group, equities research analysts predict that Zura Bio Limited will post -0.65 EPS for the current year.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.